Eicosanoids and renal vascular function in diseases. Clin Sci (Lond) 2006 Jul;111(1):21-34
Date
06/13/2006Pubmed ID
16764555DOI
10.1042/CS20050251Scopus ID
2-s2.0-33745797993 (requires institutional sign-in at Scopus site) 84 CitationsAbstract
Arachidonic acid metabolites are vital for the proper control of renal haemodynamics and, when not properly controlled, can contribute to renal vascular injury and end-stage renal disease. Three major enzymatic pathways, COX (cyclo-oxygenase), CYP450 (cytochrome P450) and LOX (lipoxygenase), are responsible for the metabolism of arachidonic acid metabolites to bioactive eicosanoids. These eicosanoids can dilate or constrict the renal vasculature and maintain vascular resistance in the face of changing vasoactive hormones. Renal vascular generation of eicosanoids is altered in pathophysiological conditions such as hypertension, diabetes, metabolic syndrome and acute renal failure. Experimental evidence supports the concept that altered eicosanoid metabolism contributes to renal haemodynamic alterations and the development and progression of nephropathy. The possible beneficial renal vascular actions of enzymatic inhibitors, eicosanoid analogues and receptor antagonists have been examined in hypertension, diabetes and metabolic syndrome. This review highlights the roles of renal vascular eicosanoids in the pathogenesis of nephropathy and therapeutic targets for renal disease related to hypertension, diabetes, metabolic syndrome and acute renal failure.
Author List
Imig JDMESH terms used to index this publication - Major topics in bold
Acute Kidney InjuryDiabetes Mellitus
Eicosanoids
Hemodynamics
Humans
Hypertension, Renal
Metabolic Syndrome
Renal Circulation
